Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 4, 2006, Pages 395-398

  Sinibaldi, Victoria J ^a,b   Elza Brown, Kathy ^a   Schmidt, Jill ^a   Eisenberger, Mario A ^a   Rosenbaum, Eli ^a   Denmeade, Samuel R ^a   Pili, Roberto ^a   Walczak, Janet ^a   Baker, Sharyn D ^a   Zahurak, Marianna ^a   Carducci, Michael A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Docetaxel; Exisulind; Prostate cancer

Indexed keywords

AMINOGLUTETHIMIDE; AMINOTRANSFERASE; ANDROGEN; CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; FLUTAMIDE; GONADORELIN DERIVATIVE; MEGESTROL ACETATE; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MLN 2704; NILUTAMIDE; PHOSPHODIESTERASE INHIBITOR; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SULINDAC SULFONE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; SULINDAC; TAXOID;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HORMONE DEPENDENCE; HUMAN; LIVER DYSFUNCTION; LUNG EDEMA; MALE; METASTASIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PROSTATE CARCINOMA; PROSTATECTOMY; RASH; STATISTICAL ANALYSIS; SURVIVAL TIME; SYNCOPE; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; SURVIVAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; SULINDAC; SURVIVAL ANALYSIS; TAXOIDS;

EID: 33746825160     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000225411.95479.b4     Document Type: Article

References (12)

1. Tannock IF, deWit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
2. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with Mitoxantrone and prednisone for advanced refractory prostate cancer (Southwest Oncology Group [SWOG] Protocol 9916). N Engl J Med. 2004;315:1513-1520.
3. Goluboff ET, Shabsigh A, Saidi JA, et al. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology. 1999;53:440-445.
4. Weinstein IB, Lim JT, Piazza GA, et al. Selective induction of apoptosis by exisulind in human prostate cancer by a novel mechanism of action (Abstract). Proc Am Soc Clin Oncol. 1999;18:355a.
5. Goluboff ET, Olsson C, Prager D, et al. Exisulind inhibits the progression of prostate cancer in men following radical prostatectomy (Abstract). J Urol. 2000;163(suppl):705.
6. Bubley GI, Carducci M, Dahut W, et al. Eligibility and response guidelines for Phase II clinical trials in androgen independent prostate cancer: recommendations from PSA Working Group. J Clin Oncol. 1999;17:1-7.
7. Baker SD, Zhao M, He P, et al. Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. Anal Biochem. 2004;324:276-284.
8. Baker SD, Zhao M, Lee CK, et al. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res. 2004;10:1976-1983.
9. De Weese TL, Van der Poel H, Li S, et al. A phase I trial of CV706 a replication-competent PSA selective oncolytic adenovirus for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001;61:7464-7472.
10. Yu DC, Chen Y, Seng M, et al. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate xenografts. Cancer Res. 1999;59:4200-4203.
11. Henry MD, Shenghua W, Silva MD, et al. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed foe the treatment of prostate cancer. Cancer Res. 2004;64:7995-8001.
12. Ryan CW, Stadler WM, Vogelsang NJ. A phase I/II dose-escalation of exisulind and docetaxel in patients with hormone-refractory prostate cancer. BJU Int. 2005;95:963-968.